Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody - PubMed (original) (raw)
Use of a novel mutagenesis strategy, optimized residue substitution, to decrease the off-rate of an anti-gp120 antibody
C M Lewis et al. Mol Immunol. 1995 Oct.
Abstract
We have developed a novel strategy to decrease the antibody:antigen off-rate which we call optimized residue substitution. This strategy employs alanine substitution to first identify residues non-optimal for binding, as evidenced by a decrease in off-rate upon alanine replacement. These positions are then individually randomized to all amino acids, and the best replacement for each position determined. Finally, a construct which combines all optimized substitutions is generated and evaluated. We applied this strategy to the heavy chain CDR3 of P5Q, a scFv antibody which recognizes an epitope on the V3 loop of HIV gp120. We identified two amino acid substitutions that together decrease the off-rate by nearly ten-fold. The contributions by the two substitutions were near additive, indicative of independent affects on binding. We suggest that this strategy can be generalized to strengthen protein:ligand and protein:protein interactions in other systems.
Similar articles
- Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig.
Neshat MN, Goodglick L, Lim K, Braun J. Neshat MN, et al. Int Immunol. 2000 Mar;12(3):305-12. doi: 10.1093/intimm/12.3.305. Int Immunol. 2000. PMID: 10700465 - CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range.
Yang WP, Green K, Pinz-Sweeney S, Briones AT, Burton DR, Barbas CF 3rd. Yang WP, et al. J Mol Biol. 1995 Dec 1;254(3):392-403. doi: 10.1006/jmbi.1995.0626. J Mol Biol. 1995. PMID: 7490758 - Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody.
Winkler K, Kramer A, Küttner G, Seifert M, Scholz C, Wessner H, Schneider-Mergener J, Höhne W. Winkler K, et al. J Immunol. 2000 Oct 15;165(8):4505-14. doi: 10.4049/jimmunol.165.8.4505. J Immunol. 2000. PMID: 11035090 - Molecular makeup of HIV-1 envelope protein.
Veljkovic V, Veljkovic N, Metlas R. Veljkovic V, et al. Int Rev Immunol. 2004 Sep-Dec;23(5-6):383-411. doi: 10.1080/08830180490432749. Int Rev Immunol. 2004. PMID: 15370272 Review.
Cited by
- Affinity improvement of the fully human anti‑TSLP recombinant antibody.
Chen Q, Xian D, Xu W, Nian S, Yu H, Wu Y, Yuan Q. Chen Q, et al. Mol Med Rep. 2020 Feb;21(2):759-767. doi: 10.3892/mmr.2019.10880. Epub 2019 Dec 12. Mol Med Rep. 2020. PMID: 31974622 Free PMC article. - Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.
Burke V, Williams C, Sukumaran M, Kim SS, Li H, Wang XH, Gorny MK, Zolla-Pazner S, Kong XP. Burke V, et al. Structure. 2009 Nov 11;17(11):1538-46. doi: 10.1016/j.str.2009.09.012. Structure. 2009. PMID: 19913488 Free PMC article. - Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.
Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A. Gorny MK, et al. Mol Immunol. 2009 Feb;46(5):917-26. doi: 10.1016/j.molimm.2008.09.005. Epub 2008 Oct 25. Mol Immunol. 2009. PMID: 18952295 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous